CardioSert

CardioSert Overview

CardioSert develops tools designed to support interventional cardiologists in percutaneous coronary intervention (PCI) procedures. The companys products include a proprietary guide wire designed for crossing complex lesions, such as chronic total occlusion (CTO), and a pressure guide wire for measuring fractional flow reserve (FFR). CardioSerts CTO tool enables the physician to gently maneuver within the microchannels that pass throughout the arterial blockage. The tool follows the microchannels in order to pass the blockage safely and quickly, allowing the delivery of balloon/stent catheters to the desired location within the blockage. The companys FFR tool acts as an off-the-shelf workhorse guide wire and is equipped with a means for sensing the level of artery recanalization or assessing the level of artery blockage pre-operation, providing the physician with an important clinical decision-making tool. CardioSerts CTO tool was licensed by Microbot Medical Inc in 2018. In May 2019, Microbot acquired a novel patent-protected technology from CardioSert and now owns CardioSerts innovative technology, including R&D information, technical know-how, and intellectual property.

Cumulative Funding Raised Over Time ($)

Latest News

May 25, 2018 · www.apnews.com

growth-positive

Microbot Medical Closes Acquisition of Novel Technology from CardioSert Ltd.

Microbot Medical Inc. has announced the acquisition of a novel patent-protected technology from CardioSert Ltd. The acquisition includes R&D information, technical know-how, and intellectual property. Microbot believes that the technology has the potential to be used in various medical applications. The company plans to leverage its existing capabilities, global IP, and recent pre-clinical results to develop highly differentiated robotic products. The acquisition was made in exchange for 100,000 restricted shares of Microbots common stock and a cash payment of $250,000, with potential additional milestone payments and earn-outs. Microbot Medical specializes in transformational micro-robotic medical technologies and is currently developing its first two product candidates: the Self Cleaning Shunt (SCS) and a self-propelling, semi-disposable endoscope. The company aims to address unmet medical needs and build a multi-generation product pipeline.

Acquisition

Apr 16, 2018 · globenewswire.com

growth-positive

Microbot Medical Exercises Option to Acquire Novel Technology from CardioSert Ltd.

Microbot Medical Inc., a medical device company, has announced the acquisition of a novel patent-protected technology from CardioSert Ltd. The acquisition strengthens Microbots IP portfolio, creates additional barriers to entry, and expands its addressable markets. The technology has the potential to be used in various medical spaces and applications. The closing of the technology acquisition is expected in late April. Microbot will exchange 100,000 restricted shares of its common stock and a cash payment of $250,000 for CardioSerts technology. Microbot is focused on developing transformational micro-robotic medical technologies, with its current platforms being the Self Cleaning Shunt (SCS) and a self-propelling, semi-disposable endoscope. The company aims to increase shareholder value and deliver on its core promises.

Acquisition

Jan 8, 2018 · www.knobbe.com

growth-positive

Microbot Medical to Acquire CardioSert's Technology

Microbot Medical Inc. has entered into an agreement to acquire CardioSert Ltd.s patented guidewire technology. The acquisition is expected to close in April 2018 and will add to Microbots patent portfolio. CardioSerts technology offers capabilities such as steering and adjustable stiffness to guidewires used in medical procedures. Microbot believes the technology has applications in other medical spaces and will enhance its existing robotic capabilities. As part of the agreement, CardioSert will receive restricted shares of Microbots common stock, cash payments, milestone payments, and royalties from future sales.

Acquisition

Jan 4, 2018 · marketexclusive.com

growth-positive

MICROBOT MEDICAL INC. (NASDAQ:MBOT) Files An 8-K Entry into a Material Definitive Agreement

Microbot Medical Inc., a medical device company, has entered into an agreement to acquire certain patent-protected technology owned by CardioSert Ltd. The acquisition is expected to close in April 2018. Microbot will make an initial payment of $50,000 and has 90 days to complete the acquisition. The Technology will be added to Microbots patent portfolio, which will then have a total of 25 issued/allowed patents and 15 patent applications pending worldwide. The acquisition aligns with Microbots strategy to develop micro-robotic technologies for surgeries and expand its intellectual property portfolio. The agreement also includes future earn-out payments based on net sales of Type 1 and Type 2 products. CardioSert will receive milestone payments upon successful animal trials and FDA approval. The agreement may be terminated by either party under certain conditions. Microbot issued a press release on January 8, 2018, regarding the agreement.

Acquisition

Funding

Team Members

2

Employees: 1-10

Web & Social Links

Locations

HaShoshanim Street 24, Nesher, Israel

Photos & Videos

2 item(s)

CardioSert Internal

Recent Updates

No update log entries.

Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.

Admin Info